Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation

World Journal of Surgical Oncology

Volumn 5, Issue , 2007, Pages

  Gillham, Charles M ^a   Reynolds, John ^a   Hollywood, Donal ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; COMPLEMENTARY DNA; CYCLINE; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METALLOTHIONEIN; PACLITAXEL; PLATINUM COMPLEX; PROTEIN P21; PROTEIN P53; SURVIVIN; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PRACTICE; CLINICAL TRIAL; DNA MICROARRAY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; GENE EXPRESSION; GENOMICS; HISTOPATHOLOGY; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; MEDLINE; MOLECULAR IMAGING; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROTEOMICS; REVIEW; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNDIFFERENTIATED CARCINOMA;

EID: 34948835668     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-5-97     Document Type: Review

References (95)

1. MINDACT, (Microarray In Node negative Disease may Avoid ChemoTherapy) (EORTC Protocol 10041 - BIG 3-04) http://www.eortc.be/services/unit/ mindact/MINDACT_websiteii.asp (Last accessed August 20, 2007)
2. Parkin DM International variation Oncogene 2004, 23:6329-6340 10.1038/ sj.onc.1207726 15322508
3. Iizuka T Isono K Kakegawa T Watanabe H Parameters linked to ten-year survival in Japan of resected esophageal carcinoma. Japanese Committee for Registration of Esophageal Carcinoma Cases Chest 1989, 96:1005-1011 2805827
4. Daly JM Karnell LH Menck HR National cancer database report on esophageal carcinoma Cancer 1996, 78:1820-1828 10.1002/ (SICI)1097-0142(19961015)78:8<1820::AID-CNCR25>3.0.CO;2-Z 8859198
5. Crew KD Neugut AI Epidemiology of upper gastrointestinal malignancies Semin Oncol 2004, 31:450-464 10.1053/j.seminoncol.2004.04.021 15297938
6. Enzinger PC Mayer RJ Esophageal Cancer N Engl J Med 2003, 349:2241-2252 10.1056/NEJMra035010 14657432
7. Altorki N Kent M Ferrara RN Port J Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus Ann Surg 2002, 236:177-183 1422563 12170022 10.1097/00000658-200208000-00005
8. Lerut T Coosemans W De Leyn P Deneffe G Topal B Van de Ven C Van Raemdonck D Reflections on 3-field lymphadenectomy in carcinoma of the esophagus and gastroesophageal junction Hepato-Gastroenterology 1999, 46:717-725 10370600
9. Suntharalingam M Moughan J Coia LR Krasna MJ Kachnic L Haller DG Willett CG John MJ Minsky BD Owen JB The national practice for patients receiving radiation therapy for carcinoma of the esophagus: Results of the 1996-1999 Patterns of Care Study Cancer 1999, 85:2499-2505 10.1002/ (SICI)1097-0142(19990615)85:12<2499::AID-CNCR2>3.0.CO;2-T 10375094
10. Geh JI Crellin AM Glynne-Jones R Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer Br J Surg 2001, 88:338-356 10.1046/j.1365-2168.2001.01670.x 11260097
11. Mandard AM Dalibard F Mandard JC Marnay J Henry-Amar M Petiot JF Roussel A Jacob JH Segol P Samama G Ollivier J-M Bonvalot SB Gignoux M Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations Cancer 1994, 73:2680-2686 10.1002/ 1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C 8194005
12. Swisher SG Hofstetter W Wu TT Correa AM Ajani JA Komaki RR Chirieac L Hunt KK Liao Z Phan A Rice DC Vaporciyan AA Walsh GL Roth JA Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pPCR) following preoperative CRT (CRT) Ann Surg 2005, 241:810-820 1357136 15849517 10.1097/01.sla.0000161983.82345.85
13. Chirieac LR Swisher SG Ajani JA Komaki RR Correa AM Morris JS Roth JA Rashid A Hamilton SR Wu TT Post therapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative CRT Cancer 2005, 103:1347-1355 10.1002/cncr.20916 15719440
14. Roth JA Pass HI Flanagan MM Graeber GM Rosenberg JC Steinberg S Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus J Cardiovasc Surg 1988, 96(2):242-248
15. Seitz JF Perrier H Monges G Giovannini M Gouvernet J Multivariate analysis of the prognostic factors of survival and the response to treatment of squamous cell oesophageal cancer by concomitant radiochemotherapy: Value of p53 immunodetection Gastroenterol Clin Biol 1995, 19:465-474 7589997
16. Kitamura K Kuwano H Araki K Egashira A Kawaguchi H Saeki H Morita M Ohno S Sugimachi K Clinicopathologic features of patients with oesophageal cancer obtaining histological complete response for preoperative hyperthermo-chemo-radiotherapy Int J Hyperthermia 1998, 14:233-243 9679703
17. Quinlan DC Davidson AG Summers CL Warden HE Doshi HM Accumulation of p53 protein correlates with a poor prognosis in human lung cancer Cancer Res 1992, 52:4828-4831 1324796
18. Thomas DJ Robinson M King P Hasan T Charlton R Martin J Carr TW Neal DE p53 expression and clinical outcome in prostate cancer Br J Urol 1993, 72:778-781 8281412
19. Smith F Reynolds J Miller N Stephens R Kennedy M Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy EJSO 2006, 32:55-64 10.1016/j.ejso.2005.09.010 16324817
20. Ribeiro U Jr Finkelstein SD Safatle-Ribeiro AV Landreneau RJ Clarke MR Bakker A Swalsky PA Gooding WE Posner MC P53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma Cancer 1998, 83:7-18 10.1002/ (SICI)1097-0142(19980701)83:1<7::AID-CNCR2>3.0.CO;2-R 9655287
21. Lowe SW Ruley HE Jacks T Houseman DE P53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 1993, 74:957-67 10.1016/ 0092-8674(93)90719-7 8402885
22. Duhaylongsod FG Gottfried MR Iglehart JD Vaughn AL Wolfe WG The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus Ann Surg 1995, 221:677-683 1234694 7794072 10.1097/00000658-199506000-00007
23. Lam KY Law S Ma LT Ong SK Wong J Pre-operative chemotherapy for squamous cell carcinoma of the oesophagus: Do histological assessment and p53 over-expression predict chemo-responsiveness? Eur J Cancer 1997, 33:1221-1225 10.1016/S0959-8049(97)00094-4 9301446
24. Wynford-Thomas D p53 in tumour pathology: Can we trust immunocytometry? J Pathol 1992, 166:329-330 10.1002/path.1711660402 1517889
25. Catalano V Baldelli AM Giordani P Cascinu S Molecular markers predictive of response to chemotherapy in gastrointestinal tumors Crit Rev Oncol Haematol 2001, 38:93-104 10.1016/S1040-8428(00)00114-1
26. el-Deiry WS Tokino T Waldman T Oliner JD Velculescu VE Burrell M Hill DE Healy E Rees JL Hamilton SR Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues Cancer Res 1995, 55:2910-2919 7796420
27. Brugarolas J Chandrasekaran C Gordon JI Beach D Jacks T Hannon GJ Radiation-induced cell cycle arrest compromized by p21 deficiency Nature 1995, 377:552-557 10.1038/377552a0 7566157
28. Nakamura T Hayashi K Ota M Ide H Takasaki K Mitsuhashi M Expression of p21(Waf1/Cip1) predicts response and survival of esophageal cancer patients treated by chemoradiotherapy Dis Oesophagus 2004, 17:315-321 10.1111/j.1442-2050.2004.00433.x
29. Nakashima S Natsugoe S Matsumoto M Kijima F Takebayashi Y Okumura H Shimada M Nakano S Kusano C Baba M Takao S Aikou T Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma Anticancer Res 2000, 20:1933-1937 10928129
30. Okumura H Natsugoe S Matsumoto M Mataki Y Takatori H Ishigami S Takao S Aikou T The predictive value of p53, p53R2, and p21 for the effect of CRT therapy on oesophageal squamous cell carcinoma Br J Cancer 2005, 92:284-289 15655547
31. Rödel F Hoffmann J Grabenbauer GG Papadopoulos T Weiss C Günther K Schick C Sauer R Rödel C High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection Strahlenther Onkol 2002, 178:426-435 10.1007/s00066-002-1003-y 12240548
32. Kato J Kuwabara Y Mitani M Shinoda N Sato A Toyama T Mitsui A Nishiwaki T Moriyama S Kudo J Fujii Y Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy Int J Cancer 2001, 95:92-95 10.1002/ 1097-0215(20010320)95:2<92::AID-IJC1016>3.0.CO;2-9 11241318
33. Warnecke-Eberz U Hokita S Xi H Higashi H Baldus SE Metzger R Brabender J Bollschweiler E Mueller RP Dienes HP Hoelscher AH Schneider PM Overexpression of survivin mRNA is associated with a favourable prognosis following neoadjuvant radiochemotherapy in esophageal cancer Oncol Rep 2005, 13:1241-1246 15870949
34. Lagarde SM ten Kate FJ Richel DJ Offerhaus GJ van Lanschot JJ Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction Ann Surg Oncol 2007, 14:977-991 10.1245/ s10434-006-9262-y 17122988
35. Chen WC McBride WH Chen SM Lee KF Hwang TZ Jung SM Shau H Liao SK Hong JH Chen MF Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: Clinical and in vitro studies Head Neck 2005, 27:503-512 10.1002/hed.20178 15772955
36. Kim YB Kim GE Pyo HR Cho NH Keum KC Lee CG Seong J Suh CO Park TK Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix Int J Radiat Oncol Biol Phys 2004, 60:822-829 10.1016/j.ijrobp.2004.04.030 15465199
37. Takatori H Natsugoe S Okumura H Matsumoto M Uchikado Y Setoyama T Sasaki K Tamotsu K Owaki T Ishigami S Aikou T Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma Eur J Surg Oncol 2007
38. Bhandari P Bateman AC Mehta RL Stacey BS Johnson P Cree IA Di Nicolantonio F Patel P Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus BMC Cancer 2006, 6:134 1481577 16712734 10.1186/ 1471-2407-6-134
39. Vaupel P Harrison L Tumor hypoxia: Causative factors, compensatory mechanisms and cellular response Oncologist 2004, 9:4-9 10.1634/ theoncologist.9-90005-4 15591417
40. Weidner N Intratumour micro vessel density as a prognostic factor in cancer Am J Pathol 1995, 147:9-19 1869874 7541613
41. Volm M Rittgen W Cellular predictive factors for the drug response of lung cancer Anticancer Res 2000, 20:3449-3458 11131647
42. Shimada H Hoshino T Okazumi S Matsubara H Funami Y Nabeya Y Hayashi H Takeda A Shiratori T Uno T Ito H Ochiai T Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma Br J Cancer 2002, 86:552-557 10.1038/ sj.bjc.6600129 11870536
43. Gorski DH Beckett MA Jaskowiak NT Calvin DP Mauceri HJ Salloum RM Seetharam S Koons A Hari DM Kufe DW Weichselbaum RR Blockade of the vascular endothelial growth factor stress response increases the anti-tumor effects of ionising radiation Cancer Res 1999, 76:3374-3378
44. Imdahl A Bognar G Schulte-Monting Schoffel U Farthmann EH Ihling C Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer Eur J Cardio-Thor Surg 2002, 21:657-663 10.1016/ S1010-7940(02)00044-1
45. Hickey K Grehan D Reid IM O'Briain S Walsh TN Hennessy TP Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy Cancer 1994, 74:1693-1698 10.1002/ 1097-0142(19940915)74:6<1693::AID-CNCR2820740609>3.0.CO;2-# 7915963
46. Wang KL Wu TT Choi IS Wang H Reseetkova E Correa AM Hofstetter WL Swisher SG Ajani JA Rashid A Albarracin CT Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: Association with poor outcome Cancer 2007, 109:658-667 10.1002/cncr.22445 17211865
47. Wright C Angus B Nicholson S Sainsbury JR Cairns J Gullick WJ Kelly P Harris AL Horne CH Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer Cancer Res 1989, 49:2087-2090 2564806
48. Brien TP Odze RD Sheehan CE McKenna BJ Ross JS HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma Hum Pathol 2000, 31:35-39 10.1016/ S0046-8177(00)80195-1 10665910
49. Akamatsu M Matsumoto T Oka K Yamasaki S Sonoue H Kajiyama Y Tsurumaru M Sasai K c-erb B-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma Int J Radiation Oncol Biol Phys 2003, 57:1323-1327 10.1016/S0360-3016(03)00782-X
50. Sarbia M Stahl M Fink U Heep H Dutkowski P Willers R Seeber S Gabbert HE Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities Int J Cancer 1999, 84:86-91 10.1002/ (SICI)1097-0215(19990219)84:1<86::AID-IJC16>3.0.CO;2-7 9988238
51. Tenderenda M A study on the prognostic value of cyclins D1 and E expression levels in respectable gastric cancer and on some correlations between cyclins expression, histoclinical parameters and selected protein products of cell-cycle regulatory genes J Exp Clin Cancer Res 2005, 24:405-414 16270527
52. Joshi MB Shirota Y Danenberg KD Conlon DH Salonga DS Herndon JE Danenberg PV Harpole DH High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer Clin Cancer Res 2005, 11:2215-2221 10.1158/ 1078-0432.CCR-04-1387 15788669
53. Janssen AM van Duijn W Kubben FJ Griffioen G Lamers CB van Krieken JH van de Velde CJ Verspaget HW Prognostic significance of metallothionein in human gastrointestinal cancer Clin Cancer Res 2002, 8:1889-1896 12060633
54. Kishi K Doki Y Miyata H Yano M Yasuda T Monden M Prediction of the response to CRT and prognosis in oesophageal squamous cancer Br J Surg 2002, 89:597-603 10.1046/j.1365-2168.2002.02057.x 11972550
55. Harpole DH Jr Moore MB Herndon JE 2nd Aloia T D'Amico TA Sporn T Parr A Linoila I Allegra C The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer Clin Cancer Res 2001, 7:562-569 11297249
56. Li Y Wo JM Cai L Zhou Z Rosenbaum D Mendez C Ray MB Jones WF Kang YJ Association of metallothionein expression and lack of apoptosis with progression of carcinogenesis in Barrett's esophagus Exp Biol Med 2003, 228(3):286-292
57. Abdel-Latif MM O'Riordan J Windle HJ Carton E Ravi N Kelleher D Reynolds JV NF-kappa B activation in esophageal adenocarcinoma: Relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy Ann Surg 2004, 239:491-500 1356254 15024310 10.1097/ 01.sla.0000118751.95179.c6
58. Izzo JG Correa AM Wu TT Malhotra U Chao CK Luthra R Ensor J Dekovich A Liao Z Hittelman WN Aggarwal BB Ajani JA Pretherapy nuclear factor-kappa B status, chemoradiation resistance, and metastatic progression in esophageal carcinoma Mol Cancer Ther 2006, 5:2844-2850 10.1158/ 1535-7163.MCT-06-0351 17121931
59. Kim YH Ajani JA Ota DM Lynch P Roth JA Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach Cancer 1995, 75:451-456 10.1002/ 1097-0142(19950115)75:2<451::AID-CNCR2820750207>3.0.CO;2-U 7812915
60. McDonnell CO Harmey JH Bouchier-Hayes DJ Walsh TN Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with esophageal cancer Br J Surg 2001, 88:1105-1109 10.1046/j.0007-1323.2001.01838.x 11488797
61. Quillien V Raoul JL Laurent JF Meunier B Le Prise E Comparison of cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma Oncol Rep 1998, 5:1561-1565 9769406
62. Nakamura T Ide H Eguchi R Hayashi K Takasaki K Watanabe S CYFRA 21-1 as a tumour marker for squamous cell carcinoma of the esophagus Dis Esophagus 1998, 11:35-39 9595230
63. Schmidt U Begley CG Cancer diagnosis and microarrays Int J Biochem Cell Biol 2003, 35:119-124 10.1016/S1357-2725(02)00124-3 12479861
64. Xu Y Selaru FM Yin J Zou TT Shustova V Mori Y Sato F Liu TC Olaru A Wang S Kimos MC Perry K Desai K Greenwald BD Krasna MJ Shibata D Abraham JM Meltzer SJ Artificial neural networks and gene filtering distinguish between global gene expression profiles of Barrett's esophagus and esophageal cancer Cancer Res 2002, 62:3493-3497 12067993
65. Dahlberg PS Ferrin LF Grindle SM Nelson CM Hoang CD Jacobson B Gene expression profiles in esophageal adenocarcinoma Ann Thorac Surg 2004, 77:1008-1015 10.1016/j.athoracsur.2003.09.051 14992916
66. McManus DT Olaru A Meltzer SJ Biomarkers of esophageal adenocarcinoma and Barrett's esophagus Cancer Res 2004, 64:1561-1569 10.1158/ 0008-5472.CAN-03-2438 14996709
67. Lu J Liu Z Xiong M Wang Q Wang X Yang G Zhao L Qiu Z Zhou C Wu M Gene expression profile changes in initiation and progression of squamous cell carcinoma of esophagus Int J Cancer 2001, 91:288-294 10.1002/ 1097-0215(200002)9999:9999<::AID-IJC1063>3.0.CO;2-S 11169949
68. Xu SH Qian LJ Mou HZ Zhu CH Zhou XM Liu XL Chen Y Bao WY Difference of gene expression profiles between esophageal carcinoma and its precancerous epithelium by gene chip World J Gastroenterol 2003, 9:417-422 12632488
69. Su H Hu N Shih J Hu Y Wang QH Chuang EY Roth MJ Wang C Goldstein AM Ding T Dawsey SM Giffen C Emmert-Buck MR Taylor PR Gene expression analysis of esophageal squamous cell carcinoma reveals consistent molecular profiles related to a family history of upper gastrointestinal cancer Cancer Res 2003, 63:3872-3876 12873975
70. Kawamata H Furihata T Omotehara F Sakai T Horiuchi H Shinagawa Y Imura J Ohkura Y Tachibana M Kubota K Terano A Fujimori T Identification of genes differentially expressed in a newly isolated human metastasizing esophageal cancer cell line, T.Tn-AT1, by cDNA microarray Cancer Sci 2003, 94:699-706 10.1111/j.1349-7006.2003.tb01505.x 12901795
71. Luthra R Wu TT Luthra MG Izzo J Lopez-Alvarez E Zhang L Bailey J Lee JH Bresalier R Rashid A Swisher SG Ajani JA Gene expression profiling of localized esophageal carcinomas: Association with pathologic response to preoperative CRT J Clin Oncol 2006, 24:259-267 10.1200/JCO.2005.03.3688 16344314
72. Agarwal B Swisher S Ajani J Kelly K Fanning C Komaki RR Putnam JB Jr Abu-Hamda E Molke KL Walsh GL Correa AM Ho L Liao Z Lynch PM Rice DC Smythe WR Stevens CW Vaporciyan AA Yao J Roth JA Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection Am J Gastroenterol 2004, 99:1258-1266 10.1111/j.1572-0241.2004.30692.x 15233663
73. Swisher SG Maish M Erasmus JJ Correa AM Ajani JA Bresalier R Komaki R Macapinlac H Munden RF Putnam JB Rice D Smythe WR Vaporciyan AA Walsh GL Wu TT Roth JA Utility of PET, CT and EUS to identify pathologic responders in esophageal cancer Ann Thorac Surg 2004, 78:1152-1160 10.1016/j.athoracsur.2004.04.046 15464463
74. Block MI Patterson GA Sundaresan RS Bailey MS Flanagan FL Dehdashti F Siegel BA Cooper JD Improvement in staging of esophageal cancer with the addition of positron emission tomography Ann Thorac Surg 1997, 64:770-776 10.1016/S0003-4975(97)00619-X 9307472
75. Flamen P Lerut A Van Cutsem E De Wever W Peeters M Stroobants S Dupont P Bormans G Hiele M De Leyn P Van Raemdonck D Coosemans W Ectors N Haustermans K Mortelmans L Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma J Clin Oncol 2000, 18:3202-3210 10986052
76. Schelling M Avril N Nährig J Kuhn W Römer W Sattler D Werner M Dose J Jänicke F Graeff H Schwaiger M Positron emission tomography using [18(F)] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 2000, 18:1689-1695 10764429
77. Thomas DM Mitchell PL Berlangieri SU Tochon-Danguy H Knight S Clarke CP Scott AM The role of positron emission tomography in assessing response to neoadjuvant chemotherapy for non-small cell lung cancer Med J Aust 1998, 169:227 Erratum in Med J Aust 1998;169:344 9734584
78. Yoshioka T Fukuda H Fujiwara T Iwata R Ido T Murakawa Y Gamo M Ishioka C Kanamaru R FDG PET evaluation of residual masses and regrowth of abdominal lymph node metastases from colon cancer compared with CT during chemotherapy Clin Nucl Med 1999, 24:261-263 10.1097/ 00003072-199904000-00009 10466523
79. Hueltenschmidt B Sautter-Bihl ML Lang O Maul FD Fischer J Mergenthaler HG Bihl H Whole body positron emission tomography in the treatment of Hodgkin disease Cancer 2001, 91:302-310 10.1002/ 1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO;2-4 11180075
80. Okada J Yoshikawa K Imazeki K Minoshima S Uno K Itami J Kuyama J Maruno H Arimizu N The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis J Nucl Med 1991, 32:686-691 2013808
81. Levine EA Farmer MR Clark P Mishra G Ho C Geisinger KR Melin SA Lovato J Oaks T Blackstock AW Predictive value of 18 FDG-PET in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer Ann Surg 2006, 243:472-478 1448953 16552197 10.1097/01.sla.0000208430.07050.61
82. Brücher BL Weber W Bauer M Fink U Avril N Stein HJ Werner M Zimmerman F Siewert JR Schwaiger M Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography Ann Surg 2001, 233:300-309 1421244 11224616 10.1097/ 00000658-200103000-00002
83. Kato H Kuwano H Nakajima M Miyazaki T Yoshikawa M Masuda N Fukuchi M Manda R Tsukada K Oriuchi N Endo K Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with oesophageal cancer Am Surg 2002, 184:279-283 10.1016/ S0002-9610(02)00932-7
84. Arslan N Miller TR Dehdashti F Battafarano RJ Siegel BA Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]Fluoro-D-Glucose with positron emission tomography in patients with esophageal cancer Mol Imag Biol 2002, 4:301-310 10.1016/ S1536-1632(02)00011-2
85. Flamen P Van Cutsem E Lerut A Cambier JP Haustermans K Bormans G De Leyn P Van Raemdonck D De Wever W Ectors N Maes A Mortelmans L Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced esophageal cancer Ann Oncol 2002, 13:361-368 10.1093/annonc/mdf081 11996465
86. Downey RJ Akhurst T Ilson D Ginsberg R Bains MS Gonen M Koong H Gollub M Minsky BD Zakowski M Turnbull A Larson SM Rusch V Whole body FDG-PET and the response of esophageal cancer to induction therapy: Results of a prospective trial J Clin Oncol 2003, 21:428-432 10.1200/JCO.2003.04.013 12560430
87. Brink I Hentschel M Bley TA Walch A Mix M Kleimaier M Moser E Imdahl A Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma Eur J Surg Oncol 2004, 30:544-550 10.1016/j.ejso.2004.03.007 15135484
88. Swisher SG Erasmus J Maish M Correa AM Macapinlac H Ajani JA Cox JD Komaki RR Hong D Lee HK Putnam JB Jr Rice DC Smythe WR Thai L Vaporciyan AA Walsh GL Wu TT Roth JA 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative CRT in patients with esophageal carcinoma Cancer 2004, 101:1776-1785 10.1002/cncr.20585 15386332
89. Song SY Kim JH Ryu JS Lee GH Kim SB Park SI Song HY Cho KJ Ahn SD Lee SW Shin SS Choi EK FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer IJROBP 2005, 63(4):1053-1059
90. Wieder HA Brücher BL Zimmermann F Becker K Lordick F Beer A Schwaiger M Fink U Siewert JR Stein HJ Weber WA Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment J Clin Oncol 2004, 22:900-908 10.1200/JCO.2004.07.122 14990646
91. Gillham M Charles Lucey A Julie Keogan Mary Duffy J George Malik Vinod Raouf A Ali O'Byrne Ken Hollywood Donal Muldoon Cian Reynolds V John Correlation of Early Quantitative changes in FDG-PET Uptake with Tumour Regression grade in patients with Localized Oesophageal cancer undergoing Neo-adjuvant Chemoradiation Br J Cancer 2006, 95:1174-1179 10.1038/sj.bjc.6603412 17024121
92. Grube D Constants and variables in immunohistochemistry Arch Histol Cytol 2004, 67:115-134 10.1679/aohc.67.115 15468952
93. Bast RC Jr Badgwell D Lu Z Marquez R Rosen D Liu J Baggerly KA Atkinson EN Skates S Zhang Z Lokshin A Menon U Jacobs I Lu K New tumor markers: CA125 and beyond Int J Gynecol Cancer 2005, 15(Suppl 3):274-281 10.1111/ j.1525-1438.2005.00441.x 16343244
94. Brown LM Helmke SM Hunsucker SW Netea-Maier RT Chiang SA Heinz DE Shroyer KR Duncan MW Haugen BR Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue Mol Carcinog 2006, 45:613-626 1899163 16788983 10.1002/ mc.20193
95. Feldman AL Espina V Petricoin EF Liotta LA Rosenblatt KP Use of proteomic patterns to screen for gastrointestinal malignancies Surgery 2004, 135:243-248 10.1016/j.surg.2003.08.019 14976472